Relafen 750 showcases a significant example within the enzymatic pharmacy landscape . The mechanism of action fundamentally targets cyclooxygenase enzymes , specifically both COX isoforms, reducing the synthesis of inflammatory mediators . From a molecular perspective , Relafen's therapeutic potential copyrights on the power to selectively inhibit